pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Kisqali
drug · small molecule
save

ribociclib succinate

Marketedupdated 3mo ago
by $NVS NOVARTIS AG🔗 ChEMBL
Approved
community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for 4 indications.

targets

Cyclin-dependent kinase 4Cyclin-dependent kinase 6

all catalysts(0)

nothing on the calendar yet

Patent cliff

source: FDA Orange Book
first barrier falls
Sep 17, 2027
~1.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (12)

  • Apr 14, 2036formulationUS 10799506
  • Apr 14, 2036formulationUS 12064434
  • Apr 14, 2036formulationUS 12419894
  • Aug 7, 2034method-of-use (U-3975)US 12544379
  • Aug 7, 2034method-of-use (U-4405)US 12544380
  • Nov 9, 2031compositionUS 9193732
  • Nov 9, 2031method-of-use (U-3266)US 9868739
  • Mar 13, 2031compositionUS 84153554.6y
  • May 25, 2030compositionUS 86859803.8y
  • Dec 9, 2029method-of-use (U-3975)US 89626303.3y
  • Aug 20, 2029method-of-use (U-3975)US 94161363.0y
  • Jun 17, 2028compositionUS 83242251.8y

FDA exclusivities (1)

  • Sep 17, 2027I-950Indication (3y)1.1y

News(3)

  • Novartis climbs on upbeat drug sales as key readouts loom
    A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.
    biopharma_dive · 24d ago
  • Novartis stays 'geography-agnostic' in dealmaking amid flurry of China deals
    Novartis will continue to be on the lookout for bolt-on deals below $2 billion, CEO Vas Narasimhan said Tuesday on the pharma's second quarter earnings call—though major pickups aren’t completely o…
    biospace · 24d ago
  • Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast Cancer
    Kelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.
    onclive · 3mo ago
brand
Kisqali
trade names
Kisqali, Ribociclib succinate component of kisqali femara co-pack
generic
ribociclib succinate
MOA
Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor
indication
Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 20m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?